Home
    Disclaimer
    ← Back to HXE
    HXE molecular structure

    HXE Stats & Data

    Dissociative Research-chemical
    Hydroxetamine 3-hydroxy-2-oxo-pce O-desmethyl methoxetamine
    NPS DataHub
    MW233.31
    FormulaC14H19NO2
    CAS1620054-73-0
    IUPAC2-(ethylamino)-2-(3-hydroxyphenyl)-cyclohexanone
    SMILESCCNC1(CCCCC1=O)c1cccc(O)c1
    InChIKeyCQERUJSORROCGH-UHFFFAOYSA-N
    Arylcyclohexylamines; 2021/6. Von Arylcyclohexylamin abgeleitete Verbindungen; 2022/6. Von Arylcyclohexylamin abgeleitete Verbindungen
    Psychoactive Class Dissociative
    Half-Life Unknown in humans; avoid assuming ketamine-like PK.

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist (noncompetitive)

    Receptor Binding

    NMDA antagonist

    History & Culture

    HXE was first identified as an active metabolite of methoxetamine (MXE), the dissociative arylcyclohexylamine that preceded it on research chemical markets. Interest in HXE as a standalone substance developed within research chemical communities, with initial announcements about its potential commercial availability appearing approximately three years before it actually became obtainable. Synthesis difficulties reportedly delayed the substance's market debut. The compound eventually appeared for sale on online research chemical markets in the late 2019 to 2020 period, transitioning from a known metabolite to a commercially available product sold in its own right.

    Effect Profile

    Curated + 1 Reports
    Dissociative 6.6

    Strong dissociative depth, motor impairment, and mania with moderate insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    8
    Insight / Novel Thought×2
    7
    Motor / Sensory Impairment×1
    10
    Based on reports from:
    Erowid Experience Reports PsychonautWiki HXE

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; avoid assuming ketamine-like PK.
    Addiction Potential
    Moderate; like other arylcyclohexylamines, rapid tolerance and compulsive redosing are reported. Cross-tolerance with ketamine/MXE-like dissociatives is likely.

    Tolerance Decay

    Full tolerance 2d Half tolerance 7d Baseline ~30d

    Model is a conservative synthesis from ketamine user reports and harm-reduction sources; high variability exists. Expect near-immediate acute tolerance within a session and partial persistence for days to weeks.

    Cross-Tolerances

    ketamine
    60% ●○○
    methoxetamine (MXE)
    60% ●○○
    other arylcyclohexylamines
    50% ●○○

    Experience Report Analysis

    Erowid
    1 Reports
    2021–2021 Date Range
    1 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Switzerland Illegal Controlled as a specially defined derivative of PCE or O-PCE under Swiss narcotics legislation. Production, possession, and distribution are prohibited.
    United Kingdom Illegal Controlled substance. As an arylcyclohexylamine with psychoactive properties, it likely falls under the Psychoactive Substances Act 2016, which prohibits the production, distribution, and possession with intent to supply of psychoactive substances.
    United States Unscheduled Not explicitly scheduled under the Controlled Substances Act. However, possession or distribution may be prosecuted under the Federal Analogue Act when intended for human consumption, as HXE is structurally related to scheduled arylcyclohexylamines. Products labeled 'not for human consumption' attempt to circumvent this provision.

    Harm Reduction

    drugs.wiki

    • Mixing dissociatives with alcohol, GHB/GBL, or opioids markedly increases risks of vomiting, loss of consciousness, and aspiration; if someone becomes unresponsive, place them in the recovery position and seek help. This advice is extrapolated from ketamine combo data and general CNS-depressant synergy.

    • Heavy/frequent ketamine use can cause lower urinary tract symptoms and ulcerative cystitis; HXE is an arylcyclohexylamine and may plausibly share this risk with chronic/high-frequency patterns even though direct human data for HXE are lacking—err on the side of caution and stop if urinary symptoms (urgency, pain, frequency, hematuria) emerge.

    • Coordination and balance can be profoundly impaired; do not drive or operate machinery and minimize fall hazards until fully baseline. NMDA-antagonist dissociation commonly causes ataxia and memory gaps.

    • Intranasal HXE is frequently described as harsh/inefficient due to poor water solubility; many report better effect per mg from oral dosing. Consider avoiding intranasal if you experience strong irritation. This is based on multiple community reports.

    • Urine immunoassay cross-reactions: PCP test false-positives are well-documented with dextromethorphan and tramadol; there is no strong evidence ketamine/HXE themselves trigger PCP positives. Confirm unexpected screens with GC/MS.

    • Ketamine elevates BP/HR in many users; dissociatives should be avoided if you have uncontrolled hypertension or significant cardiovascular disease. Apply similar caution to HXE.

    • Mislabeling is possible in the gray-market RC supply. Use reagent tests as a first pass and, where available, submit to a local drug checking service for GC/MS confirmation. Expect variability between batches.

    • Primary acute risks are sedation with emesis, ataxia, amnesia, and disorientation; ensure a calm, seated environment, avoid combining sedatives, and have a sober sitter when trialing new batches or doses.

    • Tolerance can build rapidly with repeated dosing over days; spacing sessions by multiple weeks reduces cumulative bladder, cognitive, and tolerance risks. Cross-tolerance to other arylcyclohexylamines is common. Evidence is mixed and largely anecdotal but consistent with ketamine experience.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to HXE